Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)			1 Months Ended			3 Months Ended		12 Months Ended
		Oct. 31, 2018	Dec. 31, 2023	Dec. 31, 2022	May 31, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current			$ 9,085,000			$ 7,601,000		$ 9,085,000
Deferred revenue - non-current			$ 69,794,000			67,741,000		69,794,000
Total revenue from UT						66,263,000	$ 40,626,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						24,848,000	11,386,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						18,764,000	17,562,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						47,462,000	23,027,000
United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for development of alternative manufacturing processes				$ 2,300,000
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for capital improvements				39,500,000
Thirona Bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum amount to expended									$ 1,100,000
Funded amount						900,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	[1]			722,300,000
Deferred revenue						74,000,000	77,500,000
Deferred revenue - current						7,400,000	8,900,000
Deferred revenue - non-current						$ 66,600,000	68,600,000
Royalty percentage		10.00%
Royalty future net sales percentage			1.00%
Royalty retaining percentage			9.00%
License agreement description						There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows				722,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows				$ 602,300,000
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						$ 24,464,000	11,164,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						1,300,000	1,400,000
Deferred revenue - current						100,000	200,000
Deferred revenue - non-current						1,200,000	1,200,000
Marketing and distribution agreement date					2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						$ 37,000	$ 37,000

[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.